SCHEMBL7842956

SCHEMBL7842956

CCOC(Cc1ccc(OCC=C2c3ccncc3-c3cnccc32)cc1)C(=O)O

nearest known ligand 0.75

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.75
PPARG P37231 12/20 0.75
PPARD Q03181 13/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7855453 0.96 PPARA (0.75) PPARAPPARGPPARD
SCHEMBL7843307 0.91 PPARA (0.61) PPARAPPARGPPARD
SCHEMBL7969259 0.90 PPARG (0.67) PPARAPPARGPPARD
SCHEMBL7843823 0.89 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL7855305 0.88 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL7852808 0.87 PPARA (0.68) PPARAPPARGPPARD
SCHEMBL7852809 0.87 PPARA (0.68) PPARAPPARGPPARD
SCHEMBL7850829 0.87 PPARA (0.61) PPARAPPARGPPARD
SCHEMBL6731786 0.86 PPARA (1.00) PPARAPPARGPPARD
SCHEMBL7851673 0.86 PPARG (0.67) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US claimed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP claimed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO claimed
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US disclosed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed